PMID- 36223060
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221025
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 12
IP  - 11
DP  - 2022 Nov
TI  - Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes 
      for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol 
      Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis.
PG  - 2589-2600
LID - 10.1007/s13555-022-00824-9 [doi]
AB  - INTRODUCTION: To date, there have been no head-to-head clinical studies comparing 
      calcipotriol 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam 
      and halobetasol propionate 0.01% plus tazarotene 0.045% (HP/Taz) lotion for the 
      treatment of plaque psoriasis. However, the efficacy of 4 weeks of Cal/BD foam 
      and 8 weeks of HP/Taz lotion has been compared using a matching-adjusted indirect 
      comparison (MAIC) approach. Here, we compare the efficacy and safety of Cal/BD 
      foam and HP/Taz lotion for up to 52 weeks. METHODS: An unanchored MAIC was 
      conducted using individual patient data from the PSO-LONG Cal/BD foam trial and a 
      52-week, open-label phase 3 study of HP/Taz lotion (NCT02462083). Key outcomes of 
      interest were Physician's Global Assessment (PGA) success (PGA 0/1 with >/= 2-point 
      improvement) after 4 or 8 weeks of open-label therapy; the proportion of patients 
      who had body surface area affected (BSA) </= 3 after open-label therapy who 
      maintained BSA </= 3 to week 52; and adverse events (AEs). RESULTS: After matching, 
      patients were statistically significantly more likely to have PGA success after 
      4 weeks of Cal/BD foam than after 8 weeks of HP/Taz lotion (84.5% versus 54.4%; 
      p < 0.01). At week 52, 92.5% and 92.4% of patients receiving proactive and 
      reactive Cal/BD foam, respectively, maintained BSA </= 3, compared with 49.3% of 
      those treated with HP/Taz lotion (both p < 0.01). Treatment-related AEs, AEs 
      leading to withdrawal, and AEs associated with drug application (dermatitis, 
      application site pain, and pruritus) were significantly rarer with Cal/BD foam 
      than with HP/Taz lotion (all p < 0.01). CONCLUSIONS: Cal/BD aerosol foam 
      demonstrated significantly greater efficacy than HP/Taz lotion, and had a more 
      favorable safety profile, compared with HP/Taz lotion, for up to 52 weeks. 
      Proactive Cal/BD foam maintenance therapy and reactive use of Cal/BD foam 
      following relapse both had significant advantages over HP/Taz lotion.
CI  - (c) 2022. The Author(s).
FAU - Adam, David N
AU  - Adam DN
AUID- ORCID: 0000-0003-1932-258X
AD  - Division of Dermatology, Temerty Department of Medicine, University of Toronto, 
      Toronto, ON, Canada. dnadam@gmail.com.
AD  - CCA Medical Research, Ajax, ON, Canada. dnadam@gmail.com.
AD  - Probity Medical Research, Waterloo, ON, Canada. dnadam@gmail.com.
FAU - Jablonski Bernasconi, Marie Y
AU  - Jablonski Bernasconi MY
AD  - Leo Pharma, Ballerup, Denmark.
FAU - Thoning, Henrik
AU  - Thoning H
AD  - Leo Pharma, Ballerup, Denmark.
FAU - Wu, Jashin J
AU  - Wu JJ
AD  - Department of Dermatology, University of Miami Miller School of Medicine, Miami, 
      FL, USA.
LA  - eng
PT  - Journal Article
DEP - 20221012
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC9588120
OTO - NOTNLM
OT  - Betamethasone dipropionate
OT  - Calcipotriol
OT  - Foam
OT  - Halobetasol propionate
OT  - Psoriasis
OT  - Tazarotene
EDAT- 2022/10/13 06:00
MHDA- 2022/10/13 06:01
PMCR- 2022/10/12
CRDT- 2022/10/12 11:20
PHST- 2022/09/02 00:00 [received]
PHST- 2022/09/26 00:00 [accepted]
PHST- 2022/10/13 06:00 [pubmed]
PHST- 2022/10/13 06:01 [medline]
PHST- 2022/10/12 11:20 [entrez]
PHST- 2022/10/12 00:00 [pmc-release]
AID - 10.1007/s13555-022-00824-9 [pii]
AID - 824 [pii]
AID - 10.1007/s13555-022-00824-9 [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2022 Nov;12(11):2589-2600. doi: 
      10.1007/s13555-022-00824-9. Epub 2022 Oct 12.